151 related articles for article (PubMed ID: 10590188)
1. Incidence of factor V Leiden in patients with acute myocardial infarction.
Gowda MS; Zucker ML; Vacek JL; Carriger WL; Van Laeys DL; Rachel JM; Strope BD
J Thromb Thrombolysis; 2000 Jan; 9(1):43-5. PubMed ID: 10590188
[TBL] [Abstract][Full Text] [Related]
2. [Effects of factor V Leiden mutations on prognosis in patients with acute myocardial infarction].
Baykan M; Celik S; Uçar F; Kaplan S; Ovali E; Erdöl C
Anadolu Kardiyol Derg; 2001 Dec; 1(4):242-5; AXIV. PubMed ID: 12101832
[TBL] [Abstract][Full Text] [Related]
3. [Factor V Leiden and myocardial infarction: a case, review of the literature with a meta-analysis].
Doix S; Mahrousseh M; Jolak M; Laurent Y; Lorenzini JL; Binquet C; Zeller M; Cottin Y; Wolf JE
Ann Cardiol Angeiol (Paris); 2003 Jun; 52(3):143-9. PubMed ID: 12938565
[TBL] [Abstract][Full Text] [Related]
4. Factor V Leiden and its relation to left ventricular thrombus in acute myocardial infarction.
Celik S; Ovali E; Baykan M; Uçar F; Erdöl C; Durmuş I; Kaplan S
Acta Cardiol; 2001 Feb; 56(1):1-6. PubMed ID: 11315119
[TBL] [Abstract][Full Text] [Related]
5. Factor V leiden is a risk factor for myocardial infarction in young Turkish men.
Hobikoglu GF; Akyuz U; Akyuz F; Ozer O; Güney D; Narin A; Unaltuna N
Acta Cardiol; 2004 Dec; 59(6):594-7. PubMed ID: 15636441
[TBL] [Abstract][Full Text] [Related]
6. The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation.
Bontempo FA; Hassett AC; Faruki H; Steed DL; Webster MW; Makaroun MS
J Vasc Surg; 1997 Feb; 25(2):271-5; discussion 276. PubMed ID: 9052561
[TBL] [Abstract][Full Text] [Related]
7. Age as a risk factor for myocardial infarction in Leiden mutation carriers.
Baranovskaya S; Kudinov S; Fomicheva E; Vasina V; Solovieva D; Khavinson V; Schwartz E
Mol Genet Metab; 1998 Jun; 64(2):155-7. PubMed ID: 9705241
[TBL] [Abstract][Full Text] [Related]
8. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G
Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856
[TBL] [Abstract][Full Text] [Related]
9. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women.
Rosendaal FR; Siscovick DS; Schwartz SM; Beverly RK; Psaty BM; Longstreth WT; Raghunathan TE; Koepsell TD; Reitsma PH
Blood; 1997 Apr; 89(8):2817-21. PubMed ID: 9108400
[TBL] [Abstract][Full Text] [Related]
10. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
Glueck CJ; Wang P; Fontaine RN; Tracy T; Sieve-Smith L; Lang JE
Am J Cardiol; 1999 Sep; 84(5):549-54. PubMed ID: 10482153
[TBL] [Abstract][Full Text] [Related]
11. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
[TBL] [Abstract][Full Text] [Related]
12. Frequency of factor V Leiden mutation in Egyptian cases with myocardial infarction.
Settin A; Dowaidar M; El-Baz R; Abd-Al-Samad A; El-Sayed I; Nasr M
Hematology; 2008 Jun; 13(3):170-4. PubMed ID: 18702875
[TBL] [Abstract][Full Text] [Related]
13. [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].
Ehrenforth S; Klinke S; von Depka Prondzinski M; Kreuz W; Ganser A; Scharrer I
Dtsch Med Wochenschr; 1999 Jun; 124(25-26):783-7. PubMed ID: 10414227
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction.
Middendorf K; Göhring P; Huehns TY; Seidel D; Steinbeck G; Nikol S
Am Heart J; 2004 May; 147(5):897-904. PubMed ID: 15131548
[TBL] [Abstract][Full Text] [Related]
15. Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Sartori MT; Simioni P; Patrassi GM; Theodoridis P; Tormene D; Girolami A
Clin Appl Thromb Hemost; 2000 Jan; 6(1):36-40. PubMed ID: 10726047
[TBL] [Abstract][Full Text] [Related]
16. Evidence against heterozygous coagulation factor V 1691 G-->A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction.
Prohaska W; Mannebach H; Schmidt M; Gleichmann U; Kleesiek K
J Mol Med (Berl); 1995 Oct; 73(10):521-4. PubMed ID: 8581514
[TBL] [Abstract][Full Text] [Related]
17. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Price DT; Ridker PM
Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
[TBL] [Abstract][Full Text] [Related]
18. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation.
Ridker PM; Glynn RJ; Miletich JP; Goldhaber SZ; Stampfer MJ; Hennekens CH
Ann Intern Med; 1997 Apr; 126(7):528-31. PubMed ID: 9092318
[TBL] [Abstract][Full Text] [Related]
19. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A.
Doggen CJ; Cats VM; Bertina RM; Rosendaal FR
Circulation; 1998 Mar; 97(11):1037-41. PubMed ID: 9531249
[TBL] [Abstract][Full Text] [Related]
20. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
